Biofrontera
BFRI | NASDAQ
$0.57
-$0.13 (-18.58%)
At close: Nov 16, 2026, 4:00 PM ET
$0.58
+$0.02 (+2.63%)
After-hours:
Nov 16, 2026, 5:23 PM ET
-18.58%
(1D)No price chart data available for 1D timeframe.
Rating
48.5
-5.5 ptsFundamentals Average
Market Sentiment Neutral
Moat Narrow
Sector Rank #315/1021 (Top 31%)
Key Statistics
Market Data
Market Cap $8.47M
1D Range
0.57 0.70
52W Range
0.57 1.61
Valuation (TTM)
PE -1.42
PB -34.84
EV/EBITDA -2.39
Valuation (NTM)
Forward PE 4.50
Forward PEG 0.02
Price Target $3.00
Cash Flow
FCF Yield -65.5%
SBC Adj. FCF Yield -78.8%
SBC Impact -20.2%
Margins
Gross Margin 84.6%
Operating Margin -9.5%
FCF Margin -11.5%
Growth (CAGR)
Revenue 3Y | 5Y 12.8% |
15.5%
Dil EPS 3Y | 5Y 58.1% |
65.8%
FCF 3Y | 5Y 53.0% |
33.2%
Returns
ROA -28.6%
ROE -110.3%
ROIC -59.6%
Financial Health
Net Debt
$1.53M
Current Ratio 0.78
Interest Coverage -18.41
Dividends
Div Yield N/A
Payout Ratio N/A
FCF Payout Ratio N/A
Loading financial charts...
Profile
Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. It offers Ameluz, BF-Rho...
Sector Healthcare
Industry Medical - Pharmaceuticals
Employees 89
IPO Date Oct 29, 2021
Website www.biofrontera-us.com
Fiscal Year January - December
Latest News
No news articles available yet.
Earnings
Latest Earnings
Nov 13, 2026
EPS
-$0.42
Miss -281.82%
YoY:
+28.81% REV
$9.07M
Beat +6.71%
YoY:
+29.79%Next Earnings
Mar 19, 2027
EPS Est
Pro
Rev Est
Pro
Analyst Summary
# of Analysts
1
Consensus
Buy
Price Target
$3.00
Upside
+426.32%
Buy (1)
Hold (0)
Sell (0)
Add to Watchlist
Select watchlists to add or remove BFRI